Skip to main content Skip to main navigation menu Skip to site footer
  • Register
  • Login
  • Menu
  • Home
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Register
  • Login

Quality in Sport

Basic aspects of ketamine therapy for treatment-resistant depression - a review paper
  • Home
  • /
  • Basic aspects of ketamine therapy for treatment-resistant depression - a review paper
  1. Home /
  2. Archives /
  3. Vol. 19 (2024) /
  4. Medical Sciences

Basic aspects of ketamine therapy for treatment-resistant depression - a review paper

Authors

  • Weronika Szafrańska Independent Public Health Care Complex in Minsk Mazowiecki, Szpitalna 37, 05-300 Minsk Mazowiecki https://orcid.org/0009-0004-3068-9977
  • Dominika Poborowska Stefan Zeromski Specialist Hospital, ul. Osiedle Na Skarpie 66, 31-913, Krakow https://orcid.org/0009-0000-9139-2959
  • Tomasz Gańko , Independent Public Health Care Complex in Minsk Mazowiecki, Szpitalna 37, 05-300 Minsk Mazowiecki https://orcid.org/0000-0002-9998-0453
  • Weronika Kahan Independent Public Health Care Complex in Proszowice, ul.Mikolaja Kopernika 13, 32-100, Proszowice https://orcid.org/0009-0001-1901-220X
  • Emilia Bąk Independent Public Health Care Center of the Ministry of Internal Affairs and Administration in Krakow, Kronikarza Galla 25, 30-053, Krakow https://orcid.org/0000-0002-6407-4063
  • Jacek Fordymacki Independent Public Health Care Complex in Minsk Mazowiecki, Szpitalna 37, 05-300 Minsk Mazowiecki https://orcid.org/0009-0004-5269-7687
  • Marta Wojaczek Stefan Zeromski Specialist Hospital, ul. Osiedle Na Skarpie 66, 31-913, Krakow https://orcid.org/0009-0009-7516-8151
  • Katarzyna Polańska Stefan Zeromski Specialist Hospital, ul. Osiedle Na Skarpie 66, 31-913, Krakow https://orcid.org/0009-0005-4344-1177
  • Oliwia Najjar Health Care Center in Boleslawiec, ul. Jeleniogorska 4, 59-700 Boleslawiec https://orcid.org/0009-0003-6858-3302

DOI:

https://doi.org/10.12775/QS.2024.19.53331

Keywords

ketamine, depression, treatment-resistant, antidepressant, neuronal plasticity

Abstract

Introduction and purpose: Major depressive disorder (MDD) is the most common psychiatric illness, affecting millions of people worldwide. The first line of pharmacological treatment is usually monoamine reuptake inhibitors. Up to 60% of cases, may be drug-resistant patients, prompting researchers to research substances other than conventional. 1 The purpose of this article was to review recent studies on the use of ketamine in the treatment of drug-resistant depression and present their findings.

 

Brief description of the state of knowledge: Ketamine has been a well-known drug used in anesthesiology and pain management for decades. Because of its multidirectional effects, researchers have become interested in its effects on psychiatric illnesses. Over the past decade or so, there has been a definite increase in research and articles on the use of ketamine in psychiatry. The study has resulted in FDA approval of esketamine for the treatment of treatment-resistant depression in adults in 2019.

 

Material and method: This article is the result of searching keywords on databases such as Google Scholar and Pubmed and collecting scientific literature about depression and ketamine. Articles were preselected by title, number of citations, source, and publication date.

 

Summary: Ketamine has the potential to be a treatment for drug-resistant depression. Its effectiveness varies with the form and dosage, with racemic and higher doses offering greater therapeutic benefits. Ketamine's efficacy is on par with the electroconvulsive therapy. Its onset is faster than traditional antidepressants, significantly reducing suicide risk in a shorter time frame. While the precise mechanisms of its antidepressant effects are not fully understood, it is suggested that its impact on brain neuroplasticity may contribute to the rapid onset of action. Growing evidence supports ketamine's effectiveness in treating TRD, highlighting the need for further research in this area.

References

DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV. The promise of ketamine for treatment‐resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015;1345(1):47-58. doi:10.1111/nyas.12646

Mansuri Z, Shah B, Yadav G, et al. Is Intravenous Ketamine Better Than Intranasal Esketamine for Treating Treatment-Resistant Depression? Prim Care Companion CNS Disord. 2024;26(1). doi:10.4088/PCC.23lr03607

Crisanti C, Enrico P, Fiorentini A, Delvecchio G, Brambilla P. Neurocognitive impact of ketamine treatment in major depressive disorder: A review on human and animal studies. J Affect Disord. 2020;276:1109-1118. doi:10.1016/j.jad.2020.07.119

Edinoff AN, Akuly HA, Hanna TA, et al. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurol Int. 2021;13(3):387-401. doi:10.3390/neurolint13030038

Dai D, Miller C, Valdivia V, et al. Neurocognitive effects of repeated ketamine infusion treatments in patients with treatment resistant depression: a retrospective chart review. BMC Psychiatry. 2022;22(1):140. doi:10.1186/s12888-022-03789-3

Belzung C, Willner P, Philippot P. Depression: from psychopathology to pathophysiology. Curr Opin Neurobiol. 2015;30:24-30. doi:10.1016/j.conb.2014.08.013

Sobin C. Psychomotor Symptoms of Depression. M J Psychiatry. Published online 1997.

Hofmann SG, Curtiss J, Carpenter JK, Kind S. Effect of treatments for depression on quality of life: a meta-analysis. Cogn Behav Ther. 2017;46(4):265-286. doi:10.1080/16506073.2017.1304445

Villarroel MA. Symptoms of Depression Among Adults: United States, 2019. 2020;(379).

Liu B, Liu J, Wang M, Zhang Y, Li L. From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder. Front Cell Neurosci. 2017;11:305. doi:10.3389/fncel.2017.00305

Krystal JH, Kaye AP, Jefferson S, et al. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments. Proc Natl Acad Sci. 2023;120(49):e2305772120. doi:10.1073/pnas.2305772120

Matveychuk D, Thomas RK, Swainson J, et al. Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. Ther Adv Psychopharmacol. 2020;10:204512532091665. doi:10.1177/2045125320916657

Phillips JL, Norris S, Talbot J, et al. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology. 2020;45(4):606-612. doi:10.1038/s41386-019-0570-x

Lang UE, Borgwardt S. Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies. Cell Physiol Biochem. 2013;31(6):761-777. doi:10.1159/000350094

Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018;23(4):801-811. doi:10.1038/mp.2017.255

Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2023;28(8):3243-3256. doi:10.1038/s41380-022-01661-0

Delgado PL. Depression: The Case for a Monoamine Deficiency. J Clin Psychiatry.

Leo J, Lacasse JR. The Media and the Chemical Imbalance Theory of Depression. Society. 2008;45(1):35-45. doi:10.1007/s12115-007-9047-3

Pittenger C, Duman RS. Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms. Neuropsychopharmacology. 2008;33(1):88-109. doi:10.1038/sj.npp.1301574

Albert PR. Adult neuroplasticity: A new “cure” for major depression? J Psychiatry Neurosci. 2019;44(3):147-150. doi:10.1503/jpn.190072

Huang YJ, Lane HY, Lin CH. New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity. Neural Plast. 2017;2017:1-11. doi:10.1155/2017/4605971

Derakhshanian S, Zhou M, Rath A, et al. Role of Ketamine in the Treatment of Psychiatric Disorders. Health Psychol Res. 2021;9(1). doi:10.52965/001c.25091

Na KS, Kim YK. Increased use of ketamine for the treatment of depression: Benefits and concerns. Prog Neuropsychopharmacol Biol Psychiatry. 2021;104:110060. doi:10.1016/j.pnpbp.2020.110060

Zhang C, Xu Y, Zhang B, Hao W, Tang WK. Cognitive impairment in chronic ketamine abusers. Psychiatry Res. 2020;291:113206. doi:10.1016/j.psychres.2020.113206

Jelen LA, Young AH, Stone JM. Ketamine: A tale of two enantiomers. J Psychopharmacol (Oxf). 2021;35(2):109-123. doi:10.1177/0269881120959644

Riggs LM, An X, Pereira EFR, Gould TD. (R,S)-ketamine and (2R,6R)-hydroxynorketamine differentially affect memory as a function of dosing frequency. Transl Psychiatry. 2021;11(1):583. doi:10.1038/s41398-021-01685-0

Abelaira HM, Réus GZ, Ignácio ZM, et al. Effects of ketamine administration on mTOR and reticulum stress signaling pathways in the brain after the infusion of rapamycin into prefrontal cortex. J Psychiatr Res. 2017;87:81-87. doi:10.1016/j.jpsychires.2016.12.002

Shen Z, Gao D, Lv X, Wang H, Yue W. A meta-analysis of the effects of ketamine on suicidal ideation in depression patients. Transl Psychiatry. 2024;14(1):248. doi:10.1038/s41398-024-02973-1

Karunarathna I, Kusumarathna K, Gunarathna I, et al. Ketamine: Mechanisms, Applications, and Future Directions.

Zhou Y, Wang C, Lan X, et al. Cognitive Function Mediates the Anti-suicide Effect of Repeated Intravenous Ketamine in Adult Patients With Suicidal Ideation. Front Psychiatry. 2022;13:779326. doi:10.3389/fpsyt.2022.779326

Murphy N, Tamman AJF, Lijffijt M, et al. Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacology. 2023;48(11):1586-1593. doi:10.1038/s41386-023-01586-4

Hayley S, Litteljohn D. Neuroplasticity and the next wave of antidepressant strategies. Front Cell Neurosci. 2013;7. doi:10.3389/fncel.2013.00218

Li L, Vlisides PE. Ketamine: 50 Years of Modulating the Mind. Front Hum Neurosci. 2016;10. doi:10.3389/fnhum.2016.00612

Anand A, Mathew SJ, Sanacora G, et al. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N Engl J Med. 2023;388(25):2315-2325. doi:10.1056/NEJMoa2302399

Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. Am J Psychiatry. 2018;175(4):327-335. doi:10.1176/appi.ajp.2017.17060647

Kopelman J, Keller TA, Panny B, et al. Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression. Transl Psychiatry. 2023;13(1):159. doi:10.1038/s41398-023-02451-0

Hu YD, Xiang YT, Fang JX, et al. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med. 2016;46(3):623-635. doi:10.1017/S0033291715002159

Nikolin S, Rodgers A, Schwaab A, et al. Ketamine for the treatment of major depression: a systematic review and meta-analysis. eClinicalMedicine. 2023;62:102127. doi:10.1016/j.eclinm.2023.102127

Shiroma PR, Thuras P, Wels J, et al. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. Transl Psychiatry. 2020;10(1):206. doi:10.1038/s41398-020-00897-0

Downloads

  • PDF

Published

2024-07-28

How to Cite

1.
SZAFRAŃSKA, Weronika, POBOROWSKA, Dominika, GAŃKO, Tomasz, KAHAN, Weronika, BĄK, Emilia, FORDYMACKI, Jacek, WOJACZEK, Marta, POLAŃSKA, Katarzyna and NAJJAR, Oliwia. Basic aspects of ketamine therapy for treatment-resistant depression - a review paper. Quality in Sport. Online. 28 July 2024. Vol. 19, p. 53331. [Accessed 4 July 2025]. DOI 10.12775/QS.2024.19.53331.
  • ISO 690
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 19 (2024)

Section

Medical Sciences

License

Copyright (c) 2024 Weronika Szafrańska, Dominika Poborowska, Tomasz Gańko, Weronika Kahan, Emilia Bąk, Jacek Fordymacki, Marta Wojaczek, Katarzyna Polańska, Oliwia Najjar

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Stats

Number of views and downloads: 321
Number of citations: 0

Search

Search

Browse

  • Browse Author Index
  • Issue archive

User

User

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians

Newsletter

Subscribe Unsubscribe

Tags

Search using one of provided tags:

ketamine, depression, treatment-resistant, antidepressant, neuronal plasticity
Up

Akademicka Platforma Czasopism

Najlepsze czasopisma naukowe i akademickie w jednym miejscu

apcz.umk.pl

Partners

  • Akademia Ignatianum w Krakowie
  • Akademickie Towarzystwo Andragogiczne
  • Fundacja Copernicus na rzecz Rozwoju Badań Naukowych
  • Instytut Historii im. Tadeusza Manteuffla Polskiej Akademii Nauk
  • Instytut Kultur Śródziemnomorskich i Orientalnych PAN
  • Instytut Tomistyczny
  • Karmelitański Instytut Duchowości w Krakowie
  • Ministerstwo Kultury i Dziedzictwa Narodowego
  • Państwowa Akademia Nauk Stosowanych w Krośnie
  • Państwowa Akademia Nauk Stosowanych we Włocławku
  • Państwowa Wyższa Szkoła Zawodowa im. Stanisława Pigonia w Krośnie
  • Polska Fundacja Przemysłu Kosmicznego
  • Polskie Towarzystwo Ekonomiczne
  • Polskie Towarzystwo Ludoznawcze
  • Towarzystwo Miłośników Torunia
  • Towarzystwo Naukowe w Toruniu
  • Uniwersytet im. Adama Mickiewicza w Poznaniu
  • Uniwersytet Komisji Edukacji Narodowej w Krakowie
  • Uniwersytet Mikołaja Kopernika
  • Uniwersytet w Białymstoku
  • Uniwersytet Warszawski
  • Wojewódzka Biblioteka Publiczna - Książnica Kopernikańska
  • Wyższe Seminarium Duchowne w Pelplinie / Wydawnictwo Diecezjalne „Bernardinum" w Pelplinie

© 2021- Nicolaus Copernicus University Accessibility statement Shop